Philip Haworth
Geen lopende functies
Loopbaan van Philip Haworth
Eerdere bekende functies van Philip Haworth
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
SILENCE THERAPEUTICS PLC | Directeur/Bestuurslid | 01-08-2011 | 01-08-2011 |
Algemeen Directeur | 05-01-2010 | 01-08-2011 | |
TVAX BIOM | Algemeen Directeur | 07-01-2013 | - |
CODEXIS, INC. | Corporate Officer/Principal | - | - |
AFFYMAX, INC. | Corporate Officer/Principal | - | - |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Corporate Officer/Principal | - | - |
Genencor International, Inc.
Genencor International, Inc. BiotechnologyHealth Technology Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY. | Corporate Officer/Principal | - | - |
Intradigm Corp.
Intradigm Corp. Pharmaceuticals: MajorHealth Technology Intradigm Corp. develops drugs and therapies. Its RNAi therapeutic platform comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features. The company was founded by Puthupparampil Scaria, Martin C. Woodle, Wei-Wu He and Patrick Y. Lu in 2000 and is headquartered in Palo Alto, CA. | President | 01-05-2007 | - |
Opleiding van Philip Haworth
Stanford University | Graduate Degree |
The University of Manchester | Doctorate Degree |
The University of Southampton | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 8 |
Verenigd Koninkrijk | 3 |
Israël | 2 |
Operationeel
Corporate Officer/Principal | 4 |
Chief Executive Officer | 2 |
President | 1 |
Sectoraal
Health Technology | 6 |
Consumer Services | 4 |
Process Industries | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
AFFYMAX, INC. | Health Technology |
CODEXIS, INC. | Process Industries |
SILENCE THERAPEUTICS PLC | Commercial Services |
Bedrijven in privébezit | 4 |
---|---|
Intradigm Corp.
Intradigm Corp. Pharmaceuticals: MajorHealth Technology Intradigm Corp. develops drugs and therapies. Its RNAi therapeutic platform comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features. The company was founded by Puthupparampil Scaria, Martin C. Woodle, Wei-Wu He and Patrick Y. Lu in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
Genencor International, Inc.
Genencor International, Inc. BiotechnologyHealth Technology Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY. | Health Technology |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
TVAX Biomedical, Inc.
TVAX Biomedical, Inc. BiotechnologyHealth Technology TVAX Biomedical, Inc. manufactures and sells healthcare products. It is a biotechnology company, which focuses on the development of targeted cell-based immunotherapies for the treatment of cancer and is performing clinical trials with specific focus on brain cancers. The firm’s proprietary immunologic treatment, TVAX Immunotherapy, uses a patient's cells to create activated, genetically unique cancer-killing T cells that can destroy the patient's cancer cells, including cancer stem cells, which are widely believed to be responsible for cancer growth, spread and metastasis. The company was founded by Gray W. Wood, Frank P. Holladay, Catherine E. Lucasey and Lowell Lynn Tilzer on July 14, 2011 and is headquartered in Lenexa, KS. | Health Technology |
- Beurs
- Insiders
- Philip Haworth
- Ervaring